The longevity and anti-senescence therapy market size has grown strongly in recent years. It will grow from $29.9 billion in 2025 to $31.8 billion in 2026 at a compound annual growth rate (CAGR) of 6.3%. The growth in the historic period can be attributed to increasing global aging population, early research on cellular aging mechanisms, rising prevalence of age-related diseases, historical focus on symptomatic aging treatments, growing wellness and preventive healthcare awareness.
The longevity and anti-senescence therapy market size is expected to see strong growth in the next few years. It will grow to $40.48 billion in 2030 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to advancements in senolytic and gene-based therapies, rising demand for lifespan extension solutions, increasing investments in longevity research, growing acceptance of regenerative medicine, higher healthcare spending on age-related disease prevention. Major trends in the forecast period include rising interest in healthy aging and longevity solutions, growing focus on cellular senescence targeting, increasing adoption of preventive and regenerative therapies, expansion of anti-aging treatments beyond aesthetic care, rising consumer willingness to invest in longevity therapies.
The rising prevalence of cardiovascular diseases is anticipated to drive the growth of the longevity and anti-senescence therapy market in the coming years. Cardiovascular diseases are increasing due to higher rates of risk factors such as obesity, diabetes, sedentary lifestyles, and unhealthy diets, alongside an aging population and chronic inflammation. Longevity and anti-senescence therapies aim to reduce cardiovascular disease by addressing aging-related cellular damage and enhancing overall heart health. For example, in October 2024, the Centers for Disease Control and Prevention, a US-based government agency, reported that in 2023, cardiovascular disease caused 919,032 deaths, accounting for one in every three deaths. Coronary heart disease remained the most common type of heart disease, and notably, about one in six deaths from cardiovascular diseases occurred among adults under 65 years of age. Consequently, the growing prevalence of cardiovascular diseases is fueling the expansion of the longevity and anti-senescence therapy market.
Major companies operating in the longevity and antisenescence therapy markets are forming strategic partnerships to advance anti-senescence products. Strategic partnerships are collaborative agreements between organizations that utilize each other's strengths and resources to achieve mutually beneficial objectives and enhance competitive advantage. For example, in July 2024, MDB Capital Holdings LLC, a US-based investment holding company, partnered with Mayo Clinic, a US-based nonprofit surgical and medical clinic, to expand its anti-senescence platform. This partnership aims to develop therapies targeting cellular senescence, which is linked to aging and various diseases. The collaboration will combine Mayo Clinic's expertise in clinical research with MDB Capital's innovative approach to drug development, focusing on improving patient outcomes in age-related conditions. This initiative reflects the increasing interest in addressing the biological mechanisms of aging through advanced therapeutic strategies.
In October 2023, Advantage Therapeutics Inc., a US-based company, acquired the intellectual property portfolio of Klogenix LLC for an undisclosed amount. This acquisition enhances Advantage Therapeutics' capabilities and increases its potential to develop impactful therapies for age-related diseases, significantly improving patient outcomes in a critical area of healthcare. Klogenix LLC is a US-based provider of longevity and anti-senescence therapies.
Major companies operating in the longevity and anti-senescence therapy market are AbbVie Inc., BioAge Labs, Unity Biotechnology, Insilico Medicine, Human Longevity Inc., Calico Life Sciences LLC, Recursion Pharmaceuticals, AgeX Therapeutics Inc., Alkahest Inc., CohBar Inc., Stealth BioTherapeutics, Altos Labs, Navitor Pharmaceuticals Inc., Sierra Sciences LLC, T A Sciences Inc., Juvenescence AI Limited, Senex Biotechnology, Spotlight Bioscience, Prana Biotechnology Ltd., Rejuvenate Bio Inc., Turn Biotechnologies Inc., Life Biosciences Inc.
North America was the largest region in the longevity and anti-senescence therapy market in 2025. The regions covered in the longevity and anti-senescence therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the longevity and anti-senescence therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have impacted the longevity and anti-senescence therapy market by increasing costs associated with imported biologics, advanced therapeutic inputs, and specialized laboratory equipment. These impacts are more pronounced across gene therapy, cell therapy, and senolytic drug segments, particularly in regions such as asia-pacific and europe that rely on global biotechnology supply chains. Hospitals and medical service institutions face higher treatment and research costs due to tariff pressures. However, tariffs have also encouraged localized manufacturing, regional research ecosystems, and domestic development of longevity therapies, supporting long-term market resilience.
The longevity and anti-senescence therapy market research report is one of a series of new reports that provides longevity and anti-senescence therapy market statistics, including longevity and anti-senescence therapy industry global market size, regional shares, competitors with a longevity and anti-senescence therapy market share, detailed longevity and anti-senescence therapy market segments, market trends and opportunities, and any further data you may need to thrive in the longevity and anti-senescence therapy industry. This longevity and anti-senescence therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Longevity and anti-senescence therapy encompass medical and scientific strategies aimed at prolonging human lifespan and promoting healthy aging by addressing the biological mechanisms responsible for aging, cellular damage, and the decline of bodily functions. These therapies aim to reduce or reverse senescence, the process in which cells lose their ability to divide and function effectively, contributing to aging and age-related diseases.
The primary types of longevity and anti-senescence therapies include senolytic drug therapy, gene therapy, cell therapy, mitochondrial therapy, immunotherapy, and others. Senolytic drug therapy uses medications designed to target and remove senescent cells that have stopped dividing and contribute to aging and age-related conditions. It is applied in longevity, senescence inhibition, cardiovascular diseases, neurodegenerative disorders, ophthalmology conditions, and cancer by hospitals and medical service institutions.
The longevity and anti-senescence therapy market consists of revenues earned by entities by providing services such as biomarker analysis, platelet-rich plasma (PRP) therapy, exosome therapy, bioidentical hormone replacement therapy, and anti-aging skin treatments. The market value includes the value of related goods sold by the service provider or included within the service offering. The longevity and anti-senescence therapy market also includes sales of peptide-based products, antioxidant and anti-inflammatory products, cognitive enhancers, and skincare and anti-aging cosmetics. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The longevity and anti-senescence therapy market size is expected to see strong growth in the next few years. It will grow to $40.48 billion in 2030 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to advancements in senolytic and gene-based therapies, rising demand for lifespan extension solutions, increasing investments in longevity research, growing acceptance of regenerative medicine, higher healthcare spending on age-related disease prevention. Major trends in the forecast period include rising interest in healthy aging and longevity solutions, growing focus on cellular senescence targeting, increasing adoption of preventive and regenerative therapies, expansion of anti-aging treatments beyond aesthetic care, rising consumer willingness to invest in longevity therapies.
The rising prevalence of cardiovascular diseases is anticipated to drive the growth of the longevity and anti-senescence therapy market in the coming years. Cardiovascular diseases are increasing due to higher rates of risk factors such as obesity, diabetes, sedentary lifestyles, and unhealthy diets, alongside an aging population and chronic inflammation. Longevity and anti-senescence therapies aim to reduce cardiovascular disease by addressing aging-related cellular damage and enhancing overall heart health. For example, in October 2024, the Centers for Disease Control and Prevention, a US-based government agency, reported that in 2023, cardiovascular disease caused 919,032 deaths, accounting for one in every three deaths. Coronary heart disease remained the most common type of heart disease, and notably, about one in six deaths from cardiovascular diseases occurred among adults under 65 years of age. Consequently, the growing prevalence of cardiovascular diseases is fueling the expansion of the longevity and anti-senescence therapy market.
Major companies operating in the longevity and antisenescence therapy markets are forming strategic partnerships to advance anti-senescence products. Strategic partnerships are collaborative agreements between organizations that utilize each other's strengths and resources to achieve mutually beneficial objectives and enhance competitive advantage. For example, in July 2024, MDB Capital Holdings LLC, a US-based investment holding company, partnered with Mayo Clinic, a US-based nonprofit surgical and medical clinic, to expand its anti-senescence platform. This partnership aims to develop therapies targeting cellular senescence, which is linked to aging and various diseases. The collaboration will combine Mayo Clinic's expertise in clinical research with MDB Capital's innovative approach to drug development, focusing on improving patient outcomes in age-related conditions. This initiative reflects the increasing interest in addressing the biological mechanisms of aging through advanced therapeutic strategies.
In October 2023, Advantage Therapeutics Inc., a US-based company, acquired the intellectual property portfolio of Klogenix LLC for an undisclosed amount. This acquisition enhances Advantage Therapeutics' capabilities and increases its potential to develop impactful therapies for age-related diseases, significantly improving patient outcomes in a critical area of healthcare. Klogenix LLC is a US-based provider of longevity and anti-senescence therapies.
Major companies operating in the longevity and anti-senescence therapy market are AbbVie Inc., BioAge Labs, Unity Biotechnology, Insilico Medicine, Human Longevity Inc., Calico Life Sciences LLC, Recursion Pharmaceuticals, AgeX Therapeutics Inc., Alkahest Inc., CohBar Inc., Stealth BioTherapeutics, Altos Labs, Navitor Pharmaceuticals Inc., Sierra Sciences LLC, T A Sciences Inc., Juvenescence AI Limited, Senex Biotechnology, Spotlight Bioscience, Prana Biotechnology Ltd., Rejuvenate Bio Inc., Turn Biotechnologies Inc., Life Biosciences Inc.
North America was the largest region in the longevity and anti-senescence therapy market in 2025. The regions covered in the longevity and anti-senescence therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the longevity and anti-senescence therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have impacted the longevity and anti-senescence therapy market by increasing costs associated with imported biologics, advanced therapeutic inputs, and specialized laboratory equipment. These impacts are more pronounced across gene therapy, cell therapy, and senolytic drug segments, particularly in regions such as asia-pacific and europe that rely on global biotechnology supply chains. Hospitals and medical service institutions face higher treatment and research costs due to tariff pressures. However, tariffs have also encouraged localized manufacturing, regional research ecosystems, and domestic development of longevity therapies, supporting long-term market resilience.
The longevity and anti-senescence therapy market research report is one of a series of new reports that provides longevity and anti-senescence therapy market statistics, including longevity and anti-senescence therapy industry global market size, regional shares, competitors with a longevity and anti-senescence therapy market share, detailed longevity and anti-senescence therapy market segments, market trends and opportunities, and any further data you may need to thrive in the longevity and anti-senescence therapy industry. This longevity and anti-senescence therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Longevity and anti-senescence therapy encompass medical and scientific strategies aimed at prolonging human lifespan and promoting healthy aging by addressing the biological mechanisms responsible for aging, cellular damage, and the decline of bodily functions. These therapies aim to reduce or reverse senescence, the process in which cells lose their ability to divide and function effectively, contributing to aging and age-related diseases.
The primary types of longevity and anti-senescence therapies include senolytic drug therapy, gene therapy, cell therapy, mitochondrial therapy, immunotherapy, and others. Senolytic drug therapy uses medications designed to target and remove senescent cells that have stopped dividing and contribute to aging and age-related conditions. It is applied in longevity, senescence inhibition, cardiovascular diseases, neurodegenerative disorders, ophthalmology conditions, and cancer by hospitals and medical service institutions.
The longevity and anti-senescence therapy market consists of revenues earned by entities by providing services such as biomarker analysis, platelet-rich plasma (PRP) therapy, exosome therapy, bioidentical hormone replacement therapy, and anti-aging skin treatments. The market value includes the value of related goods sold by the service provider or included within the service offering. The longevity and anti-senescence therapy market also includes sales of peptide-based products, antioxidant and anti-inflammatory products, cognitive enhancers, and skincare and anti-aging cosmetics. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Longevity and Anti-senescence Therapy Market Characteristics
3. Longevity and Anti-senescence Therapy Market Supply Chain Analysis
4. Global Longevity and Anti-senescence Therapy Market Trends and Strategies
5. Longevity and Anti-senescence Therapy Market Analysis of End Use Industries
7. Global Longevity and Anti-senescence Therapy Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Longevity and Anti-senescence Therapy Total Addressable Market (TAM) Analysis for the Market
9. Longevity and Anti-senescence Therapy Market Segmentation
10. Longevity and Anti-senescence Therapy Market Regional and Country Analysis
11. Asia-Pacific Longevity and Anti-senescence Therapy Market
12. China Longevity and Anti-senescence Therapy Market
13. India Longevity and Anti-senescence Therapy Market
14. Japan Longevity and Anti-senescence Therapy Market
15. Australia Longevity and Anti-senescence Therapy Market
16. Indonesia Longevity and Anti-senescence Therapy Market
17. South Korea Longevity and Anti-senescence Therapy Market
18. Taiwan Longevity and Anti-senescence Therapy Market
19. South East Asia Longevity and Anti-senescence Therapy Market
20. Western Europe Longevity and Anti-senescence Therapy Market
21. UK Longevity and Anti-senescence Therapy Market
22. Germany Longevity and Anti-senescence Therapy Market
23. France Longevity and Anti-senescence Therapy Market
24. Italy Longevity and Anti-senescence Therapy Market
25. Spain Longevity and Anti-senescence Therapy Market
26. Eastern Europe Longevity and Anti-senescence Therapy Market
27. Russia Longevity and Anti-senescence Therapy Market
28. North America Longevity and Anti-senescence Therapy Market
29. USA Longevity and Anti-senescence Therapy Market
30. Canada Longevity and Anti-senescence Therapy Market
31. South America Longevity and Anti-senescence Therapy Market
32. Brazil Longevity and Anti-senescence Therapy Market
33. Middle East Longevity and Anti-senescence Therapy Market
34. Africa Longevity and Anti-senescence Therapy Market
36. Longevity and Anti-senescence Therapy Market Competitive Landscape and Company Profiles
37. Longevity and Anti-senescence Therapy Market Other Major and Innovative Companies
40. Longevity and Anti-senescence Therapy Market High Potential Countries, Segments and Strategies
41. Appendix
Executive Summary
Longevity And Anti-senescence Therapy Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses longevity and anti-senescence therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for longevity and anti-senescence therapy? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The longevity and anti-senescence therapy market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Therapy: Senolytic Drug Therapy; Gene Therapy; Cell Therapy; Mitochondrial Therapy; Immunotherapy2) By Application: Longevity; Senescence Inhibition; Cardiovascular Diseases; Neural Degenerative Diseases; Ophthalmology Disorders; Cancer
3) By End User: Hospital; Medical Service Institution
Subsegments:
1) By Senolytic Drug Therapy: Small Molecule Senolytics; Natural Senolytics; Combination Senolytic Treatments2) By Gene Therapy: CRISPR-Based Gene Therapy; Viral Vector Gene Therapy; RNA Interference Therapy
3) By Cell Therapy: Stem Cell Therapy; Immune Cell Therapy; Regenerative Cell Therapy
4) By Mitochondrial Therapy: Mitochondrial Replacement Therapy; Mitochondrial Enhancement Compounds; Mitochondrial Gene Therapy
5) By Immunotherapy: Monoclonal Antibodies; Immune Checkpoint Inhibitors; Vaccines For Aging
Companies Mentioned: AbbVie Inc.; BioAge Labs; Unity Biotechnology; Insilico Medicine; Human Longevity Inc.; Calico Life Sciences LLC; Recursion Pharmaceuticals; AgeX Therapeutics Inc.; Alkahest Inc.; CohBar Inc.; Stealth BioTherapeutics; Altos Labs; Navitor Pharmaceuticals Inc.; Sierra Sciences LLC; T A Sciences Inc.; Juvenescence AI Limited; Senex Biotechnology; Spotlight Bioscience; Prana Biotechnology Ltd.; Rejuvenate Bio Inc.; Turn Biotechnologies Inc.; Life Biosciences Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Longevity and Anti-senescence Therapy market report include:- AbbVie Inc.
- BioAge Labs
- Unity Biotechnology
- Insilico Medicine
- Human Longevity Inc.
- Calico Life Sciences LLC
- Recursion Pharmaceuticals
- AgeX Therapeutics Inc.
- Alkahest Inc.
- CohBar Inc.
- Stealth BioTherapeutics
- Altos Labs
- Navitor Pharmaceuticals Inc.
- Sierra Sciences LLC
- T A Sciences Inc.
- Juvenescence AI Limited
- Senex Biotechnology
- Spotlight Bioscience
- Prana Biotechnology Ltd.
- Rejuvenate Bio Inc.
- Turn Biotechnologies Inc.
- Life Biosciences Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 31.8 Billion |
| Forecasted Market Value ( USD | $ 40.48 Billion |
| Compound Annual Growth Rate | 6.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 23 |
